NICE
This article was originally published in The Gray Sheet
Executive Summary
National Institute for Clinical Excellence (NICE) guidance to the UK's National Health Service focusing on the clinical and cost effectiveness of implantable cardioverter defibrillators (ICDs), released Sept. 29, recommends three-fold increase in utilization rate by Britons, from an estimated 17 per million in the population to 50 per million. The change could bring the usage rate in line with that of other European countries. The NICE guidance follows an extensive review of published clinical data and information submitted by ICD manufacturers (1"The Gray Sheet" Sept. 18, 2000, p. 15)....Separately, artificial hip joints become the first medical device category where performance data will be available to UK National Health Service trusts following the April release of a NICE guidance on hip prostheses. The central database will inform trusts of devices that best meet their requirements
You may also be interested in...
UK's NICE Could Issue ICD Guidance As Early As Sept. 25 - ABHI Officials
The National Institute for Clinical Excellence (NICE) guidance to the UK's National Health Service focusing on the clinical and cost effectiveness of implantable cardioverter defibrillators (ICDs) could be issued as early as the week of Sept. 25.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.